MET and hepatocellular carcinoma: Specific c‐Met inhibitors, such as tivantinib (Rota Caremoli and Labianca, 2014; Santoro et al., 2013) and foretinib (Yau et al., 2012), have been clinically trialed in the treatment for HCC.